Seeking Alpha

Merck's (MRK) odanacatib osteoporosis drug significantly increased hip and spine bone mineral...

Merck's (MRK) odanacatib osteoporosis drug significantly increased hip and spine bone mineral density in a phase two trial of post-menopausal women who had previously taken the company's Fosamax treatment. "Odanacatib may be a viable alternative for patients who need continued therapy and who want benefits beyond what they (already) received," Merck said. (PR)
Comments (1)
  • vallies
    , contributor
    Comments (351) | Send Message
     
    The drug stocks are holding up like a champ. I was going to purchase MRK at 42. I am looking at LLY just on evaluation and dividend. I also like LFC; A Chinese Health Care play, but it's yealy dividend was almost cut in half. Plus I don't know what I am looking at with ADR's. Any suggestions out there.
    14 Oct 2012, 08:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs